Northland Securities Thinks Flexion Therapeutics’ Stock is Going to Recover


In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $20. The company’s shares closed yesterday at $11, close to its 52-week low of $9.90.

According to TipRanks.com, Byrnes is a 1-star analyst with an average return of -5.9% and a 18.2% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Heron Therapeutics.

Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20, which is an 81.8% upside from current levels. In a report issued on March 28, Raymond James also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Flexion Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $40.58 million. In comparison, last year the company had a GAAP net loss of $41.57 million.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FLXN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts